Microneedling for Hair Loss: What the Research Shows and How to Do It Safely

By Dr. Susan Lin, MD | MD HAIR | La Cañada Ventures, Inc.

There is a derma roller in your cart right now, or maybe already in your bathroom drawer. It cost less than a dinner out. The reviews are glowing, the before-and-after photos are persuasive, and somewhere along the way you read that rolling it over your scalp and then applying your serum “boosts absorption by 80%.”

I want to talk about that last sentence, because it is simultaneously true and one of the more dangerous pieces of advice circulating in the hair-loss world.

Microneedling for hair loss is not a fad. It has a plausible, well-described mechanism, a real randomized trial behind it, and a legitimate place in hair medicine. I recommend it to appropriate patients. But it is also the one at-home hair intervention that can genuinely hurt you — through infection, through scarring, and through exactly the “boosted absorption” everyone is so excited about. Puncturing skin is a medical procedure, and it does not stop being one because the device arrived in the mail.

As a physician who has formulated topicals for nearly two decades, let me give you the mechanism, the honest evidence, and — at greater length than you will find elsewhere — the safety rules that actually matter.

The Mechanism: Controlled Injury as a Growth Signal

Microneedling works on a counterintuitive principle: you deliberately create thousands of tiny, controlled wounds in order to recruit the body’s repair machinery. It is the same logic behind percutaneous collagen induction in dermatology (Aust et al., 2008). Applied to the scalp, three things follow.

1. The wound-healing cascade and growth factor release

Micro-punctures trigger the standard three-phase healing response — inflammation, proliferation, remodeling. Within minutes, platelets aggregate and degranulate, releasing a burst of signaling molecules: platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), and transforming growth factor-beta.

Several of these are directly relevant to hair. VEGF drives angiogenesis, expanding the perifollicular capillary network that supplies the dermal papilla. PDGF is implicated in the anagen induction pathway. In effect, microneedling floods the follicular neighborhood with the same signaling molecules that accompany the transition out of telogen and into active growth.

2. Wnt/β-catenin signaling

This is the more interesting layer. Wnt/β-catenin is the master pathway governing hair follicle development and cycling — it is what tells a follicle to build a hair.

The landmark demonstration came from Ito and colleagues in Nature, who showed that wounding adult mouse skin could induce genuinely de novo hair follicle formation, and that the process was Wnt-dependent (Ito et al., 2007). Blocking Wnt abolished the regeneration; augmenting it increased follicle numbers. That paper is the intellectual foundation for wound-based hair therapies — the demonstration that injury signals and follicle-building signals are the same signals.

I will add the caveat I always add: that was a mouse study of de novo follicle neogenesis, which is not the same claim as “a derma roller will grow new follicles on your head.” What it establishes is the mechanistic link between controlled wounding and Wnt activation. That link is real. Its magnitude in human scalp is far less certain.

3. Dermal papilla stem cell activation

Microneedling has been proposed to activate stem cells in the bulge region and to upregulate hair-growth-related genes in dermal papilla cells. The preclinical data here are suggestive rather than definitive, and I present it as a hypothesis rather than a settled mechanism.

The Evidence: Dhurat et al., 2013 — and What It Actually Showed

The trial everyone cites is Dhurat and colleagues, published in the International Journal of Trichology in 2013.

Sixty men with androgenetic alopecia were randomized to one of two arms: 5% minoxidil twice daily alone, or 5% minoxidil twice daily plus weekly microneedling with a 1.5mm derma roller. The study ran twelve weeks with blinded evaluator assessment and hair counts (Dhurat et al., 2013).

The result was striking. At twelve weeks, the microneedling-plus-minoxidil group showed a mean change in hair count of roughly 91 hairs per square centimeter versus about 22 in the minoxidil-only group. On the seven-point investigator assessment, and on patient self-assessment, the combination group did substantially better. A follow-up report from the same group described response in men who had previously failed conventional therapy (Dhurat & Mathapati, 2015).

Read the design carefully, though, because it determines what you can conclude:

This was an add-on study, not a head-to-head. Both arms received minoxidil. The trial tells you microneedling added benefit on top of minoxidil. It does not tell you microneedling works on its own, and it does not tell you how it compares to minoxidil alone as a substitute.

Sixty men, twelve weeks, single site. That is pilot scale and a short window for hair biology. There was no sham-needling arm.

And here is the part almost nobody addresses: in that protocol, minoxidil was applied to skin that had been punctured. Which brings us to the most important section in this article.

The Safety Section: Please Read This Before You Roll

I am going to be more emphatic here than I usually am, because this is where at-home microneedling actually causes harm.

Do NOT apply active topicals immediately after microneedling

The stratum corneum is your skin’s barrier, and it is the single greatest determinant of how much of any topical enters your bloodstream. Microneedling’s entire purpose is to breach it — thousands of times, in a small area. For roughly 24 hours afterward, that skin is not behaving like intact skin. It is behaving like an open channel.

Applying an active compound to freshly microneedled scalp does not “boost absorption” in a gentle, helpful way. It converts a topical product into something far closer to a systemic one, at a dose nobody has characterized.

This applies with particular force to minoxidil. Minoxidil is, at its origin, a potent antihypertensive vasodilator; topical use depends on the fact that only a small percentage crosses intact skin. Remove the barrier and that assumption fails. Reported consequences of increased systemic minoxidil exposure include headache, dizziness, palpitations, tachycardia, fluid retention, and ankle edema. The product’s own over-the-counter labeling directs that it not be used when the scalp is red, inflamed, infected, irritated, or painful — freshly needled skin is broken skin by definition.

The same principle applies to essential oils, retinoids, vitamin C serums, and any product containing preservatives, fragrance, or alcohol. There is a well-documented case series in JAMA Dermatology of facial allergic granulomatous reactions and systemic hypersensitivity following microneedling with topicals applied during the procedure — a vivid reminder that ingredients tolerated on intact skin can behave very differently when introduced through it (Soltani-Arabshahi et al., 2014).

The practical rule I give patients: separate them by at least 24 hours. Microneedle on one day; apply your actives on the other days. If you use minoxidil, discuss the specific timing with your prescribing physician — this is a medication decision, not a lifestyle one, and I am not in a position to adjust anyone’s prescribed regimen from a blog post.

Device hygiene and infection risk

A derma roller is a multi-use device that repeatedly punctures skin. That is, in infection-control terms, a serious object.

The scalp carries a dense resident flora — Staphylococcus, Cutibacterium, Malassezia. Microneedling drives surface organisms into the dermis. Folliculitis is the common outcome; cellulitis and abscess are the uncommon but real ones.

Non-negotiables if you proceed: disinfect the device with 70% isopropyl alcohol for at least ten minutes before and after every use, allow it to air dry fully on a clean surface, store it in its case, never share it with another person, and never use it over active acne, pustules, warts, or infected skin — you will seed the organism across the whole treated field.

Why at-home rollers dull and tear

This is the mechanical problem, and it is underappreciated.

A microneedling pen stamps needles in and out along their own axis, producing clean vertical channels. A roller drags an arc across the surface, so each needle enters at an angle, sweeps, and exits at an angle. Even when new, this produces more tissue disruption than a stamp. As the needles dull with use — and steel micro-needles dull quickly, often within a handful of sessions — the roller stops puncturing and starts tearing.

Tearing is a different injury from puncturing. It produces irregular, wider wounds, more inflammation, and a meaningfully higher risk of the outcome you least want on a scalp: scarring.

If you use a roller, replace it on a fixed schedule — every 8 to 10 sessions at most — and inspect the needle bed under bright light for bent or missing needles before each use. A bent needle is a laceration waiting to happen.

Scarring, and why the scalp is unforgiving

Scarring on the scalp is not a cosmetic footnote. Scar tissue is fibrotic tissue, and follicles do not grow through it. A microneedling injury severe enough to scar has permanently removed follicular potential from that patch — the exact opposite of the goal. This is the reason I am firm about depth, technique, and device condition. Everywhere else on the body, an overly aggressive session leaves a mark. On the scalp, it can leave a bald spot.

Depth and frequency

Published scalp protocols cluster around 1.0–1.5mm, which is the depth used in the Dhurat trial. Deeper is not better; it is simply more injurious, and the pain and bleeding it produces are not evidence of efficacy.

Frequency matters just as much. The trial protocol was weekly, and even that is on the aggressive side for home use. Healing and remodeling take time; needling before the previous injury has resolved produces chronic inflammation rather than a healing cascade. Every one to two weeks is a reasonable ceiling. More often is not more effective — it is cumulative trauma.

Who should not microneedle at all

This list is not hedging. Each item reflects a real mechanism of harm.

  • Active scalp infection — bacterial, fungal, or viral. Needling disseminates it.
  • Seborrheic dermatitis or psoriasis flare — you are needling inflamed skin, and psoriasis in particular can exhibit the Koebner phenomenon, where new lesions appear at sites of trauma.
  • Keloid or hypertrophic scarring tendency — including a family history, and with particular attention for patients with darker skin tones, who carry higher keloid risk. If you have ever formed a raised scar, do not microneedle without a dermatologist’s assessment.
  • Anticoagulants or antiplatelet therapy — warfarin, DOACs, clopidogrel, or regular aspirin. Bleeding and hematoma risk rise substantially. This requires your prescriber’s input, not your own judgment.
  • Isotretinoin, current or within the past 6–12 months — isotretinoin alters sebaceous function and dermal wound healing and is classically associated with atypical scarring after procedures. Wait, and clear it with your dermatologist.
  • Bleeding disorders, uncontrolled diabetes, or immunosuppression — impaired healing and elevated infection risk.
  • Active alopecia areata or any suspected scarring alopecia — lichen planopilaris, frontal fibrosing alopecia, central centrifugal cicatricial alopecia. Trauma can worsen these conditions, and they require diagnosis and treatment, not needling.
  • Pregnancy — insufficient safety data, and the topical questions become more complicated.

My honest recommendation on who should hold the device

Given all of the above, my clinical preference is that scalp microneedling be performed by, or at minimum initially supervised by, a physician or licensed professional — a dermatologist, a trained aesthetician working under medical oversight, or your treating clinician. Professional devices are sterile-tipped, single-use, and depth-calibrated. The provider can confirm your diagnosis first, which matters enormously: needling a scarring alopecia that was mistaken for pattern loss is an actively harmful choice.

If you are going to do it at home anyway, do it after a diagnosis, at 1.0–1.5mm, no more than weekly, with a rigorously disinfected and frequently replaced device, and with a 24-hour gap before any active topical.

Where Microneedling Fits in a Drug-Free Regimen

Microneedling is a stimulus, not a treatment for the underlying cause. It does not lower DHT, correct ferritin, fix a thyroid, or change your hormonal environment. It provokes a growth signal in follicles that still have the capacity to respond.

That has two implications. First, it works best on follicles that are miniaturized but not yet fibrosed — early-to-moderate loss, not slick bald scalp. Second, it is most sensible layered on top of a corrected foundation, not instead of one. Before I would have anyone puncture their scalp weekly, I want their serum ferritin (target above 70 ng/mL for hair purposes, well above the lab-normal cutoff — Trost et al., 2006), full thyroid panel, vitamin D, and zinc on paper and corrected.

A reasonable weekly architecture looks like this: one microneedling day, six days of topical support, nutritional foundation running continuously underneath, and photographs on a fixed schedule so you are judging results with evidence rather than mood.

The Bottom Line

Microneedling has a coherent mechanism — controlled micro-injury recruiting growth factors and Wnt signaling — and one genuine randomized trial showing meaningful added benefit when combined with minoxidil over twelve weeks. That is more than most things in this category can claim, and it is why I take it seriously.

But it is a procedure, not a product. The risks are real and specific: infection from a contaminated device, tearing and scarring from a dull one, permanent follicle loss from a scar, and — most commonly missed — dramatically increased systemic absorption of whatever you apply to freshly breached skin. That last one is not a theoretical concern for minoxidil users. It is the most likely way an enthusiastic person gets hurt.

Get a diagnosis first. Get a professional to perform it, or at least to teach you. Keep the depth at 1.0–1.5mm and the frequency to weekly at most. Sterilize obsessively and replace the device often. And separate the needling from the actives by a full day.

Do it that way and microneedling is a reasonable, evidence-supported addition to a hair regimen. Do it the way the internet describes it — roll, then immediately saturate the scalp with whatever is on the shelf — and you have taken a real risk for no additional benefit.

Dr. Susan Lin’s Clinical Perspective

“The Dhurat data are good enough that I do recommend microneedling — to the right patient, at the right depth, performed properly. What alarms me is the single most repeated piece of advice online: roll, then immediately apply your serum. That instruction inverts the safety logic entirely. You have just removed the stratum corneum’s protection across thousands of channels; that is precisely the moment to apply nothing. With minoxidil the concern is concrete — it is an antihypertensive whose topical safety margin depends on poor penetration, and you have just eliminated the poor penetration. Second, please stop reusing a six-month-old roller. Dull needles tear rather than puncture, and scalp scarring is permanent follicle loss. And third: get a diagnosis before you needle. I have seen frontal fibrosing alopecia treated at home with a derma roller for a year. That is not a delay in treatment — it is trauma applied to a scarring condition.”

— Dr. Susan F. Lin, M.D., Physician Formulator, MD HAIR

Mechanism Spotlight: Why the Stratum Corneum Is the Whole Safety Margin

Every topical product’s safety profile rests on one assumption: that most of it stays out. The stratum corneum — roughly fifteen layers of flattened, keratin-filled corneocytes embedded in a lipid matrix — is why. It is the reason a molecule can be applied to skin in quantities that would be pharmacologically significant if swallowed, and remain largely local.

Topical minoxidil is the clearest illustration. As an oral drug it is a potent antihypertensive with meaningful cardiovascular effects. As a topical it is tolerable specifically because only a small fraction of the applied dose crosses intact skin — the barrier, not the molecule, provides the safety margin (Messenger & Rundegren, 2004). The over-the-counter labeling accordingly warns against use on a scalp that is red, inflamed, infected, irritated, or painful.

Microneedling removes that margin deliberately. A 1.5mm needle passes entirely through epidermis into dermis, and at typical roller densities a single session opens thousands of such channels — bypassing the barrier and delivering directly into vascularized tissue. Barrier recovery is not instantaneous; transepidermal water loss studies after percutaneous collagen induction show measurable disruption persisting for many hours to about a day (Aust et al., 2008).

So the 24-hour separation rule is not caution for its own sake. It is the time the barrier needs to reassemble before it can do the job every topical’s dosing assumes it is doing.

Recommended Reading

Pillar pages on mdhair.com:

Related articles in this series:

Not sure where your hair loss fits? Take the MD HAIR Quiz.

Our official sister site, md-factor.com, hosts the broader MD® science library if you would like to go deeper on formulation topics.

MD HAIR Product Recommendation

MD® Follicle Energizer — Hair Density Scalp Serum

Important timing note first: apply on non-microneedling days, or exactly as your physician directs. Nothing in this recommendation should be read as encouragement to apply any topical to freshly needled skin — including this one. Give the barrier its 24 hours.

On the other six days, the MD® Follicle Energizer is the drug-free topical I formulated for the hairline, crown, and part line, where thinning shows first. It delivers Biotinoyl Tripeptide-1 at a defined concentration, with a precision brush applicator that places product on scalp rather than on hair. Because it is drug-free and hormone-free, it fits alongside a microneedling schedule without adding a pharmacologic variable, and there is no rebound shedding if you stop.

In a 119-day (17-week) open-label study conducted by Spincontrol North America on the two-step topical serum system (n=24, no placebo arm, outcomes self-reported by questionnaire), 71% of participants agreed their hair growth had improved. The report itself cautions that the overall satisfaction rate was “not significantly validated.” Individual results vary.

The nutritional foundation mentioned above can run continuously underneath any microneedling schedule, because it is internal rather than topical: MD Nutri Hair™, one capsule daily. Its key botanical is lilac stem-cell extract standardized for verbascoside, a plant phenol which in controlled laboratory studies on human dermal papilla cells induced cell proliferation, prevented testosterone-induced cell death, and reduced the release of pro-inflammatory signals including IL-1α, IL-6, IL-1β and TNF-α (Wisuitiprot et al., 2022). These are cell studies, not human trials; the authors state that clinical study is still needed.

Genuine MD HAIR and MD Nutri Hair™ products are sold only through mdhair.com, md-factor.com, and the official La Cañada Ventures, Inc. stores on Amazon and Walmart. We cannot authenticate products purchased through any other channel.

References

  1. Dhurat R, Sukesh M, Avhad G, Dandale A, Pal A, Pund P. (2013). A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia: a pilot study. International Journal of Trichology, 5(1), 6–11. PubMed
  2. Dhurat R, Mathapati S. (2015). Response to microneedling treatment in men with androgenetic alopecia who failed to respond to conventional therapy. Indian Journal of Dermatology, 60(3), 260–263. PubMed
  3. Ito M, Yang Z, Andl T, et al. (2007). Wnt-dependent de novo hair follicle regeneration in adult mouse skin after wounding. Nature, 447(7142), 316–320. PubMed
  4. Aust MC, Fernandes D, Kolokythas P, Kaplan HM, Vogt PM. (2008). Percutaneous collagen induction therapy: an alternative treatment for scars, wrinkles, and skin laxity. Plastic and Reconstructive Surgery, 121(4), 1421–1429. PubMed
  5. Soltani-Arabshahi R, Wong JW, Duffy KL, Powell DL. (2014). Facial allergic granulomatous reaction and systemic hypersensitivity associated with microneedle therapy for skin rejuvenation. JAMA Dermatology, 150(1), 68–72. PubMed
  6. Messenger AG, Rundegren J. (2004). Minoxidil: mechanisms of action on hair growth. British Journal of Dermatology, 150(2), 186–194. PubMed
  7. Trost LB, Bergfeld WF, Calogeras E. (2006). The diagnosis and treatment of iron deficiency and its potential relationship to hair loss. Journal of the American Academy of Dermatology, 54(5), 824–844. PubMed
  8. U.S. Food and Drug Administration. (2020). Regulatory Considerations for Microneedling Products: Guidance for Industry and Food and Drug Administration Staff. FDA.gov
  9. Over-the-counter drug labeling for topical minoxidil 5%: do not use when the scalp is red, inflamed, infected, irritated, or painful. DailyMed

Dr. Susan F. Lin, M.D. is the physician formulator behind MD HAIR, a line of drug-free, clinically informed hair products by La Cañada Ventures, Inc., physician-formulated since 2008. MD HAIR topical products are cosmetics; they are not intended to diagnose, treat, cure, or prevent any disease. MD Nutri Hair™ is a dietary supplement. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Manufactured in FDA-registered, GMP-compliant facilities in the USA; facility registration is not product approval by the FDA. This article is for educational purposes and does not constitute medical advice. Microneedling is a procedure that breaks the skin; discuss it with your own physician before beginning, and do not start, stop, or change any medication without your prescriber’s guidance. Because there are no clinical data in pregnant or breastfeeding women, we do not advocate using MD HAIR products during pregnancy or lactation.